Citadel Advisors’s CONMED CNMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.73M Sell
246,930
-393,643
-61% -$16M ﹤0.01% 3444
2025
Q4
$26M Buy
640,573
+585,407
+1,061% +$25.5M ﹤0.01% 2059
2025
Q3
$2.59M Buy
55,166
+35,056
+174% +$1.82M ﹤0.01% 5562
2025
Q2
$1.05M Buy
+20,110
New +$1.1M ﹤0.01% 6980
2025
Q1
Sell
-28,631
Closed -$1.85M 14599
2024
Q4
$1.96M Buy
28,631
+14,534
+103% +$1.01M ﹤0.01% 5669
2024
Q3
$1.01M Sell
14,097
-224,428
-94% -$15.8M ﹤0.01% 6842
2024
Q2
$16.5M Buy
238,525
+82,442
+53% +$6.01M ﹤0.01% 2195
2024
Q1
$12.5M Buy
156,083
+141,413
+964% +$12.6M ﹤0.01% 2639
2023
Q4
$1.61M Sell
14,670
-20,257
-58% -$2.09M ﹤0.01% 5767
2023
Q3
$3.52M Sell
34,927
-174,141
-83% -$20M ﹤0.01% 4210
2023
Q2
$28.4M Buy
209,068
+205,228
+5,344% +$25.1M 0.01% 1534
2023
Q1
$399K Sell
3,840
-377,562
-99% -$36.5M ﹤0.01% 8777
2022
Q4
$33.8M Buy
381,402
+241,877
+173% +$20.1M 0.01% 1444
2022
Q3
$11.2M Buy
139,525
+48,350
+53% +$4.56M ﹤0.01% 2612
2022
Q2
$8.73M Sell
91,175
-76,211
-46% -$9.15M ﹤0.01% 2868
2022
Q1
$24.9M Buy
167,386
+147,605
+746% +$20.6M 0.01% 1740
2021
Q4
$2.8M Sell
19,781
-120,993
-86% -$17.1M ﹤0.01% 5469
2021
Q3
$18.4M Buy
140,774
+53,831
+62% +$7.04M ﹤0.01% 2121
2021
Q2
$11.9M Sell
86,943
-193
-0.2% -$26.4K ﹤0.01% 2808
2021
Q1
$11.4M Buy
87,136
+60,792
+231% +$7.32M ﹤0.01% 2788
2020
Q4
$2.95M Buy
26,344
+2,723
+12% +$258K ﹤0.01% 4612
2020
Q3
$1.86M Sell
23,621
-10,719
-31% -$874K ﹤0.01% 4844
2020
Q2
$2.47M Sell
34,340
-33,135
-49% -$2.31M ﹤0.01% 4185
2020
Q1
$3.86M Buy
67,475
+16,847
+33% +$1.55M ﹤0.01% 3085
2019
Q4
$5.66M Sell
50,628
-47,571
-48% -$5.07M ﹤0.01% 2927
2019
Q3
$9.44M Buy
98,199
+50,925
+108% +$4.78M ﹤0.01% 2287
2019
Q2
$4.04M Sell
47,274
-174,588
-79% -$14.4M ﹤0.01% 3408
2019
Q1
$18.5M Buy
221,862
+178,613
+413% +$13M 0.01% 1412
2018
Q4
$2.78M Sell
43,249
-130,715
-75% -$8.94M ﹤0.01% 3647
2018
Q3
$13.8M Buy
173,964
+26,949
+18% +$2.08M 0.01% 1743
2018
Q2
$10.8M Buy
147,015
+143,599
+4,204% +$9.77M 0.01% 1860
2018
Q1
$216K Sell
3,416
-31,505
-90% -$1.88M ﹤0.01% 7235
2017
Q4
$1.78M Buy
34,921
+30,333
+661% +$1.58M ﹤0.01% 3794
2017
Q3
$241K Sell
4,588
-19,816
-81% -$995K ﹤0.01% 6396
2017
Q2
$1.24M Sell
24,404
-49,723
-67% -$2.46M ﹤0.01% 3789
2017
Q1
$3.29M Buy
74,127
+53,556
+260% +$2.3M ﹤0.01% 2478
2016
Q4
$909K Sell
20,571
-89,033
-81% -$3.78M ﹤0.01% 3987
2016
Q3
$4.39M Buy
109,604
+103,643
+1,739% +$4.4M ﹤0.01% 2110
2016
Q2
$285K Buy
+5,961
New +$252K ﹤0.01% 5290
2016
Q1
Sell
-13,716
Closed -$604K 6906
2015
Q4
$604K Sell
13,716
-10,510
-43% -$456K ﹤0.01% 4209
2015
Q3
$1.16M Buy
24,226
+22,555
+1,350% +$1.24M ﹤0.01% 3627
2015
Q2
$97K Sell
1,671
-3,744
-69% -$202K ﹤0.01% 7101
2015
Q1
$273K Buy
5,415
+3,554
+191% +$174K ﹤0.01% 5785
2014
Q4
$84K Buy
1,861
+658
+55% +$27.6K ﹤0.01% 6786
2014
Q3
$44K Sell
1,203
-97,798
-99% -$3.88M ﹤0.01% 6973
2014
Q2
$4.37M Buy
99,001
+44,924
+83% +$2.04M 0.01% 1954
2014
Q1
$2.35M Buy
54,077
+41,763
+339% +$1.86M ﹤0.01% 2485
2013
Q4
$523K Sell
12,314
-10,330
-46% -$393K ﹤0.01% 3976
2013
Q3
$770K Buy
+22,644
New +$739K ﹤0.01% 3365

Other funds holding CNMD

Citadel Advisors's CNMD Position: Q1 2026 in Review

Citadel Advisors reduced its CONMED (CNMD) stake by 61% in Q1 2026, selling an estimated $16M and leaving 246,930 shares worth $8.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3444.

Citadel Advisors first reported a position in CNMD in Q3 2013 and has held it in 49 quarters since. The position peaked at $33.8M in Q4 2022. 236 funds tracked by Wall St. Rank hold CNMD as of Q1 2026.

  • Citadel Advisors held 246,930 shares of CONMED worth $8.73M as of Q1 2026.
  • Citadel Advisors sold 393,643 CONMED shares in Q1 2026, an estimated $16M.
  • CONMED made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3444 holding.
  • Citadel Advisors first reported a position in CONMED in Q3 2013 and has held it in 49 quarters since.
  • Citadel Advisors's CONMED position peaked at $33.8M in Q4 2022.
  • 236 funds tracked by Wall St. Rank held CONMED as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.